Reuben D B, Mor V, Hiris J
Division of General Internal Medicine, Rhode Island Hospital, Providence 02903.
Arch Intern Med. 1988 Jul;148(7):1586-91.
Planning terminal care for patients with malignant neoplasms is difficult, in part, because accurate measures of prognosis have not been defined. Using data from the National Hospice Study, we examined the correlation of 14 easily assessable clinical symptoms with survival in patients with terminal cancer. Performance status was the most important clinical factor in estimating survival time, but five other symptoms had independent predictive value as well (shortness of breath, problems eating or anorexia, trouble swallowing, dry mouth, and weight loss). We generated four parametric accelerated time survival models to estimate survival in patients with combinations of these symptoms and validated the log-normal model on the entire data set. This model was unaffected by patient age, sex, primary tumor type, or site. Our findings illustrate the value of biologically "soft" clinical data in predicting survival in patients with terminal cancer. The prevalence of similar symptoms among patients with cancer of various primary and metastatic sites also supports the concept of a common final clinical pathway in patients with advanced malignant neoplasms.
为恶性肿瘤患者规划临终护理颇具难度,部分原因在于尚未明确准确的预后衡量标准。利用国家临终关怀研究的数据,我们研究了14种易于评估的临床症状与晚期癌症患者生存率之间的相关性。体能状态是估计生存时间的最重要临床因素,但其他五种症状也具有独立的预测价值(呼吸急促、进食问题或厌食、吞咽困难、口干和体重减轻)。我们生成了四个参数加速时间生存模型,以估计出现这些症状组合的患者的生存率,并在整个数据集上验证了对数正态模型。该模型不受患者年龄、性别、原发肿瘤类型或部位的影响。我们的研究结果说明了生物学上“软性”临床数据在预测晚期癌症患者生存率方面的价值。各种原发和转移部位癌症患者中类似症状的普遍性也支持了晚期恶性肿瘤患者存在共同最终临床路径的概念。